Literature DB >> 3264510

Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis.

A Kapp1, A Piskorski, E Schöpf.   

Abstract

Elevated levels of serum interleukin 2 receptor (IL2R) represent an early measure of T cell activation. The concentration of IL2R was measured in the sera of patients with atopic dermatitis (n = 58) or psoriasis, without psoriatic arthritis, (n = 26), who had moderate to severe disease activity, and in non-atopic healthy controls (n = 37) by an ELISA technique. Serum IL2R levels were found to be significantly elevated in both disease groups compared with the controls. The increase in serum IL2R may be due to T cell activation in the dermis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264510     DOI: 10.1111/j.1365-2133.1988.tb03491.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  16 in total

1.  Quantitation of soluble CD27, a T-cell activation antigen, and soluble interleukin-2 receptor in serum from patients with psoriasis.

Authors:  M A de Rie; F Hamerlinck; R Q Hintzen; J D Bos; R A van Lier
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

2.  Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.

Authors:  J I Duncan; C Horrocks; A D Ormerod; A V Powles; P H Whiting; L Fry; A W Thomson
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

3.  Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease.

Authors:  E Dagli; J A Warner; C R Besley; J O Warner
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

4.  Interleukin 2, soluble interleukin 2 receptor, and interferon-gamma in the suction blister fluids from psoriatic skin.

Authors:  H Takematsu; H Tagami
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

5.  sICAM-1, sIL-2R and beta 2-microglobulin serum levels in patients affected with psoriasis: relationship with disease severity.

Authors:  M Carducci; A Mussi; C Bonifati; M Fazio; F Ameglio
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

6.  Ichthyosis bullosa of Siemens: further delineation of the phenotype.

Authors:  P M Steijlen; C M Perret; J H Schuurmans Stekhoven; D J Ruiter; R Happle
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

7.  The development of manifest psoriatic lesions is linked with the appearance of ICAM-1 positivity on keratinocytes.

Authors:  K Paukkonen; A Naukkarinen; M Horsmanheimo
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

8.  Enhanced procoagulant activity of mononuclear leukocytes in patients with atopic dermatitis and psoriasis.

Authors:  R E Schopf; H Weber; B Morsches
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

9.  Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis.

Authors:  B Wüthrich; M K Kägi; H Joller-Jemelka
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

10.  The interleukin-2 receptor in lesions and serum of bullous pemphigoid.

Authors:  D Zillikens; A Ambach; M Schuessler; R Dummer; A A Hartmann; G Burg
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.